Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

Summary

This is multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of patients with mild to moderate COVID-19. This is a phase 2 study of cysteamine-pantetheine disulfide (TTI-0102), an antiviral, anti-infectious, antioxidant and anti-CRS (cytokine release syndrome) investigational drug. Subjects will be randomized 2:1 to receive TTI-0102 or placebo daily for up to 14 days. Up to 5 centers in the US and Canada will conduct this study. 60 patients will be enrolled.

Timeline

Start

2024-09-27

Primary completion

2024-09-27

Completion

2024-09-27

Outcome

Outcome not reported

Stopped: “Sponsor is not pursuing the COVID-19 indication at this time.”

Drugs

Indications